Palivizumab
From Wikipedia, the free encyclopedia
|
Palivizumab
|
|
|
|
|
| Source | Humanized |
| Target | RSV |
| Identifiers | |
| CAS number | |
| ATC code | J06 |
| DrugBank | |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 18-20 days |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C |
| Legal status | |
| Routes | IM |
Palivizumab (brand name Synagis) is a monoclonal antibody produced by recombinant DNA technology. It is used in the prevention of Respiratory Syncytial Virus (RSV) infections. It is recommended for premature infants born before 32 weeks of gestation and for infants less than two years of age who suffer from severe chronic lung disease.
Palivizumab targets the fusion protein of RSV.[1] Inhibiting its entry into the cell and thereby preventing infection.
[edit] References
- ^ Levinson, Wilson. "Medical Microbiology and Immunology, 8th ed." Lange: 2004. p. 430.
 |
This medical treatment article is a stub. You can help Wikipedia by expanding it. |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Alemtuzumab, Apolizumab, Aselizumab, Atlizumab, Bapineuzumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Cedelizumab, Certolizumab pegol, Cidfusituzumab, Cidtuzumab, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Felvizumab, Fontolizumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Mepolizumab, Motavizumab, Motovizumab, Natalizumab, Nimotuzumab, Nolovizumab, Numavizumab, Ocrelizumab, Omalizumab, Palivizumab, Pascolizumab, Pecfusituzumab, Pectuzumab, Pertuzumab, Pexelizumab, Ralivizumab, Ranibizumab, Reslivizumab, Reslizumab, Resyvizumab, Rovelizumab, Ruplizumab, Sibrotuzumab, Siplizumab, Sontuzumab, Tacatuzumab tetraxetan, Tadocizumab, Talizumab, Tefibazumab, Tocilizumab, Toralizumab, Trastuzumab, Tucotuzumab celmoleukin, Tucusituzumab, Umavizumab, Urtoxazumab, Visilizumab
